Sun, 16/01/2011 - 16:28 by Neka Sehgal
In what can be termed as yet another blow to Johnson & Johnson, which has been struggling with manufacturing and quality control troubles for well over a year, the company is recalling almost 47 million units of over-the-counter medicines due to inadequate cleaning procedures.
Fri, 10/12/2010 - 07:13 by harsheeb
NewBrunwick -- Johnson & Johnson is recalling about 13 million packages of Rolaids Softchews the company says may contain metal and wood particles.
In a statement, the company said the "foreign materials" were "potentially introduced into the product during the manufacturing process by a third party manufacturer" and that "the risk of serious adverse health consequences is remote," WebMD.com reported Thursday.
The action is the latest in a series of recalls affecting J&J's McNeil division this year. The company recalled various lots of Mylanta, Tylenol, Children's Benadryl, Junior Strength Motrin and Pepcid products.
Sat, 27/11/2010 - 22:54 by harsheeb
Washington -- Federal inspectors said a Johnson & Johnson drug making plant in Puerto Rico had yet to meet quality control standards spelled out by letter in January.
The plant operated by McNeil Consumer Healthcare, a unit of the Johnson & Johnson conglomerate, recalled millions of bottles of over the counter drugs, including Tylenol and Motrin, in January, The New York Times reported Saturday.
Johnson & Johnson also recalled 136 million bottles of liquid children's Tylenol and other medicines in April, although these were made in Pennsylvania, the Times said.
Wed, 24/11/2010 - 13:35 by Neha Gupta
In yet another recall, Johnson & Johnson subsidiary McNeil Consumer Healthcare has called back almost 5 million packages of two children’s medicines.
Sat, 30/10/2010 - 22:33 by Anand Chokkavelu
I love bargain stocks, especially when they're hitting 52-week lows. Still, it can be instructive to also look at stocks that are riding high.
Tue, 26/10/2010 - 12:31 by Morgan Housel
There are many ways to value a company. Price to earnings. Price to cash flow. Liquidation value. Price per eyeballs on website. Price to a number I completely made up (this one never gets old). Price to CEO's ego divided by lobbying activity as a percentage of revenue (this one doesn't get used enough).
Wed, 20/10/2010 - 11:22 by Brian Orelli
The greatest thing going for Johnson & Johnson (NYSE: JNJ) is its diversity in product offerings.
Wed, 29/09/2010 - 14:58 by Jamie Anderson
The Food and Drug Administration (FDA) continued to crack the whip on marketers who make unproven claims in their advertising campaigns when it issued warning letters to three sellers of mouth-rinse products.
Sat, 04/09/2010 - 11:05 by Morgan Housel
Bond bubble talk is rife these days. Maybe it's because we've become, as one economist put it, "armageddon hypochondriacs." Recent experience leads us to believe that markets are always on the brink of insanity and meltdown.
Tue, 24/08/2010 - 12:09 by Jacob Roche
Johnson & Johnson (NYSE: JNJ) recently broke a new record -- but it wasn't for the strongest Tylenol in history. J&J has now posted the lowest yields ever on a corporate 10-year and 30-year bond -- 2.95% and 4.50% respectively. For comparison's sake, that's 21 and 56 basis points more than comparable Treasury bonds.